The dimerization status of CtBP is a potential marker for predicting the sensitivity of ovarian cancer patients to platinum-based drugs and is also a target for improving the therapeutic efficacy of platinum-based drugs in ovarian cancer [54]. The gene discussed is CTBP1; the disease is ovarian cancer.